PAIN
Volume 118, Issue 1 , Pages 23-34 , November 2005

A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats

Received 11 November 2004 ,Revised 27 June 2005 ,Accepted 18 July 2005.

References 

  1. Akerley W. Paclitaxel in advanced non-small cell lung cancer: an alternative to high-dose weekly schedule. Chest. 2000;117:152S–155S
  2. Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 1996;73:259–265
  3. Authier N, Fialip J, Eschalier A, Coudore F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett. 2000;291(2):73–76
  4. Authier N, Gillet JP, Filiap J, Eschalier A, Coudore F. Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res. 2000;887:239–249
  5. Bennett GJ, Hargreaves KM. Reply to Hirata and his colleagues. Pain. 1990;42:255
  6. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107
  7. Besse D, Lombard MC, Besson JM. Time-related decreases in mu and delta opioid receptors in the superficial dorsal horn of the rat spinal cord following a large unilateral dorsal rhizotomy. Brain Res. 1992;578(1–2):115–127
  8. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133:586–594
  9. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 1991;9:1261–1267
  10. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;75:1141–1150
  11. Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol. 1995;133:64–72
  12. Chapman V. Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology. 2001;41:870–877
  13. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35:304–311
  14. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynaecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol. 1996;62:166–168
  15. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci. 2000;15:510–521
  16. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997;35:47–53
  17. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001;92:91–100
  18. Gordon AN, Stringer CA, Matthws CM, Willis DL, Nemunaitis J. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. J Clin Oncol. 1997;15:1965–1973
  19. Helsing M, Thaning L, Sederholm C, Lamberg K, Martinsson JE, Ek L, et al. Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Lung Cancer. 1999;24:107–113
  20. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain. Neurosci Lett. 1997;221:157–160
  21. Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, Horton J, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 1973;33:1258–1264
  22. Kupers RC, Nuytten D, De Castro-Costa M, Gybels JM. A time analysis of the changes on spontaneous and evoked behaviour in a rat model of neuropatic pain. Pain. 1992;50:101–111
  23. Langer CJ, McAleer C, Bonjo CA, Litwin S, Millenson M, Kosierowski R, et al. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). Eur J Cancer. 2000;36:183–193
  24. Li J, Daughters RS, Bullis C, Bengiamin R, Stucky MW, Brennan J, et al. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain. 1999;81:25–33
  25. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther. 1991;258:517–523
  26. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 1996;276(2):585–593
  27. Lim G, Sung B, Ji RR, Mao J. Up-regulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003;105(1–2):275–283
  28. Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, et al. Taxol produces a predominantly sensory neuropathy. Neurology. 1989;39:368–373
  29. Malan TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah TW, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 2001;93:239–245
  30. Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci. 1996;16:6601–6611
  31. Martin WJ, Loo CM, Basbaum A. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 1999;82:199–205
  32. McGuire WP, Hoskins WJ, Brady BS, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med. 1996;334:1–6
  33. Monhemius R, Azami J, Green DL, Roberts MH. CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res. 2001;908:67–74
  34. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. Vincristine-induced allodynia in the rat. Pain. 2001;93:69–73
  35. Pertwee RG. The ring test: a quantitative method for assessing the cataleptic effects of cannabis in mice. Br J Pharmacol. 1972;46:753–763
  36. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol. 1992;105:980–984
  37. Polomano RC, Mannes AJ, Clark US, Bennet GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001;94:293–304
  38. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 1998;345:145–153
  39. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 1998;75:111–119
  40. Rowinsky EK, Donehower RC. Paclitaxel (taxol). New Engl J Med. 1995;332:1004–1014
  41. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247–1259
  42. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (TAXOL®). Semin Oncol. 1993;20(Suppl. 3):1–15
  43. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study in fifty leukemic patients. Neurology. 1969;19:367–374
  44. Scott DA, Wright CE, Angus JA. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain. 2004;109(1–2):124–131
  45. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol. 2001;415:R5–R7
  46. Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav. 1998;60:183–191
  47. Sofia RD, Nalepa SD, Harakal JJ, Vassar HB. Antiedema and analgesic propierties of delta9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther. 1973;186:646–655
  48. van den Bent MJ, Van Raaij-van Aassen VJ, Verweij J, Doorn PA, Sillevis Smitt PA. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve. 1997;20:750–752
  49. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hchster H, et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol. 1996;14:1993–1999
  50. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther. 1998;286:1301–1308
  51. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987;5:1232–1239
  52. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987;47:2486–2493
  53. Yaksh TL. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in rat. J Clin Pharmacol. 1981;2:334S–340S
  54. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16:109–110

PII: S0304-3959(05)00368-4

doi: 10.1016/j.pain.2005.07.008

PAIN
Volume 118, Issue 1 , Pages 23-34 , November 2005

Article Tools

* Image Usage & Resolution